LENZ

LENZ Therapeutics, Inc.

5.94 USD

Last updated Sep 4, 20:18 UTC

Yesterday HIGH

$5.97

Yesterday LOW

$5.65

52w HIGH

$50.19

52w LOW

$4.54

EPS

-1.02

PE

-5.82

Next Earnings

Nov 4, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

LENZ Therapeutics, Inc. stock is up 12.71% since 30 days ago. The next earnings date is Nov 4, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 5 September’s closed higher than August. In the last 4 Unusual Options Trades, there were 3 CALLs, 1 PUT. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

15 Jul 14:28	19 Mar, 2027	5.00	CALL	216	9
15 Jul 14:37	19 Mar, 2027	5.00	CALL	243	9
13 Aug 18:38	15 Jan, 2027	2.50	CALL	112	101
17 Aug 16:25	19 Mar, 2027	7.50	PUT	77	433

Advanced Data Unlock

Benzinga Newsdesk

Wed Jun 24, 2026

LENZ Therapeutics And Arrotex Pharma Announce Exclusive License And Commercialization Agreement For Arrotex To Register And Commercialize VIZZ For Treatment Of Presbyopia In Australia And New Zealand

LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Arrotex Pharmaceuticals Pty Ltd. ("Arrotex") today announced an exclusive license and commercialization agreement for Arrotex to register and commercialize VIZZ™ for the
Benzinga Newsdesk

Mon Jun 8, 2026

Reported Sunday, LENZ Therapeutics' VIZZ Eye Drop Gains Greater China Partner As Everest Medicines Acquires Rights Ahead Of Anticipated Q1 2027 Approval
Benzinga Newsdesk

Wed May 13, 2026

Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $26 to $20.
Benzinga Newsdesk

Tue May 12, 2026

LENZ Therapeutics shares are trading lower after the company reported mixed Q1 financial results. Also, Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $39 to $12.
Benzinga Newsdesk

Tue May 12, 2026

HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $38

HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $48 to $38.
Benzinga Newsdesk

Tue May 12, 2026

Piper Sandler Downgrades LENZ Therapeutics to Neutral, Lowers Price Target to $12

Piper Sandler analyst Biren Amin downgrades LENZ Therapeutics (NASDAQ:LENZ) from Overweight to Neutral and lowers the price target from $39 to $12.
Benzinga Newsdesk

Mon May 11, 2026

LENZ Therapeutics Q1 EPS $(1.32) Misses $(1.05) Estimate, Sales $1.901M Beat $1.759M Estimate

LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.05) by 25.71 percent. This is a 149.06 percent decrease over losses of $(0.53) per share
Benzinga Insights

Mon May 11, 2026

Earnings Scheduled For May 11, 2026
Benzinga Newsdesk

Tue Apr 21, 2026

HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $48

HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $56 to $48.
Benzinga Newsdesk

Mon Apr 20, 2026

LENZ Therapeutics Files Marketing Authorization Application Review, Approval Of VIZZ To Medicines And Healthcare products Regulatory Agency To Treat Presbyopia In Adults

LENZ Therapeutics, Inc. (NASDAQ:LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for the review

Piper Sandler

Wed Aug 12, 18:23

hold

confirm

Advanced Data Unlock

MSTX MSTX $16.80 USD

LULU $100.57 USD

PSKY $10.87 USD

BETR BETR $14.46 USD

SNDK $1,738.83 USD

LRCX $307.56 USD

AAPL $319.87 USD

SMCI $39.60 USD

DIA $533.85 USD